- Home
- ARMN vs BBNX Comparison
ARMN vs BBNX Comparison
Compare ARMN & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMN
- BBNX
- Stock Information
- Founded
- ARMN 1992
- BBNX 2015
- Country
- ARMN Canada
- BBNX United States
- Employees
- ARMN N/A
- BBNX N/A
- Industry
- ARMN
- BBNX Medical/Dental Instruments
- Sector
- ARMN
- BBNX Health Care
- Exchange
- ARMN Nasdaq
- BBNX Nasdaq
- Market Cap
- ARMN 769.7M
- BBNX 866.3M
- IPO Year
- ARMN N/A
- BBNX 2025
- Fundamental
- Price
- ARMN $4.97
- BBNX $10.74
- Analyst Decision
- ARMN
- BBNX Strong Buy
- Analyst Count
- ARMN 0
- BBNX 6
- Target Price
- ARMN N/A
- BBNX $26.67
- AVG Volume (30 Days)
- ARMN 853.8K
- BBNX 670.0K
- Earning Date
- ARMN 05-13-2025
- BBNX 05-06-2025
- Dividend Yield
- ARMN N/A
- BBNX N/A
- EPS Growth
- ARMN 77.15
- BBNX N/A
- EPS
- ARMN 0.14
- BBNX N/A
- Revenue
- ARMN $510,604,000.00
- BBNX $65,123,999.00
- Revenue This Year
- ARMN $49.45
- BBNX $29.49
- Revenue Next Year
- ARMN $4.63
- BBNX $34.93
- P/E Ratio
- ARMN $34.83
- BBNX N/A
- Revenue Growth
- ARMN 14.06
- BBNX 442.93
- 52 Week Low
- ARMN $3.29
- BBNX $10.63
- 52 Week High
- ARMN $5.16
- BBNX $24.50
- Technical
- Relative Strength Index (RSI)
- ARMN 69.07
- BBNX N/A
- Support Level
- ARMN $4.50
- BBNX N/A
- Resistance Level
- ARMN $4.88
- BBNX N/A
- Average True Range (ATR)
- ARMN 0.21
- BBNX 0.00
- MACD
- ARMN 0.04
- BBNX 0.00
- Stochastic Oscillator
- ARMN 86.09
- BBNX 0.00
About ARMN Aris Mining Corporation
Aris Mining Corp is engaged in the acquisition, exploration, development and operation of gold properties in Colombia, Guyana and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, Toroparu Project in Guyana and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product include the iLet Bionic Pancreas (iLet). The Company operates as single segment, focused on the development, manufacture and sale of the iLet.